News
August 30, 2023
New Investigational Therapy for Lupus Treatment, GLPG3667, Begins Phase 2 Study
A new investigational therapy, GLPG3667, for adults with active lupus is beginningPhase 2 study to examine the safety, tolerability and efficacy of the treatment. The therapy is a tyrosine kinase 2 or TYK2 enzyme inhibitor, which prevents inflammation. TYK2 is a critical driver of disease in lupus.
The GALACELA trial will enroll approximately 140 adults with lupus who will receive the treatment orally once per day or placebo for 32 weeks.
Continue to follow the Lupus Foundation of America for updates on GLPG3667 as well as other lupus clinical trials.
See More:
The latest from Inside Lupus Research
News
Differences in Disease Activity by Onset-Age in People with Systemic Lupus Erythematosus
News
Neighborhood Disadvantage Associated with Lower Testing and Physician Access in Young People with Systemic Lupus Erythematosus Despite Insurance Coverage
News
Study Reveals Depression is Often Undiagnosed in People with Systemic Lupus Erythematosus
News
Drug Update: First Person Dosed with Investigational Therapy AlloNK for Lupus Nephritis